In Brief

Rapid coronavirus test approved by the FDA

PCR tests work by detecting specific genetic material within the virus.
PCR tests work by detecting specific genetic material within the virus. (Image credit: Shutterstock)

The U.S. Food and Drug Administration (FDA) has given emergency approval to a test that could diagnose COVID-19 in 45 minutes, CNN reported.

The tests were developed by California-based company Cepheid and will be shipped to U.S. facilities by March 30, according to an FDA announcement. However, right now, the tests are likely only going to be used in a hospital setting, where a patient is already in an emergency room or hospital triage wing and needs to be diagnosed rapidly, STAT reported

"We don't believe this technology should be used, at least initially, in a doctor's office," David Persing, chief medical officer of Cepheid, told STAT. "This is not a test for the worried well."

Related: 13 coronavirus myths busted by science

Partly, that's because Cepheid's production capacity is limited; it can produce millions of tests over the coming weeks, Persing told STAT. By contrast, other companies with approved tests will be able to produce millions of tests per week by April, according to STAT.

The U.S. has been plagued by a severe shortage of tests, which allowed the new coronavirus SARS-CoV-2 to spread undetected for weeks. Test kits initially sent by the Centers for Disease Control and Prevention were faulty, and for weeks the government forbade local labs from developing their own kits.

Testing has ramped up significantly in the past two weeks, and as a result, the number of confirmed cases in the country has skyrocketed. As of Saturday (March 21), the U.S. had logged more than 24,000 cases, more than half in the state of New York.

As nearly every country in the world races to diagnose and contain new cases, the U.S. is now facing competition for supplies, such as swabs and chemical reagents, that are needed to run the tests. 

ABCmouse - 1 Month Free!

<a href="https://www.tkqlhce.com/click-6361382-12795772?sid=hawk-custom-tracking" data-link-merchant="tkqlhce.com"" target="_blank" rel="nofollow">ABCmouse - 1 Month Free!

The one-month trial gives you access to all of the educational site's 9,000 activities in reading, science, math and art. Keep your child busy and learning while we are all stuck indoors.

Tia Ghose
Managing Editor

Tia is the managing editor and was previously a senior writer for Live Science. Her work has appeared in Scientific American, Wired.com and other outlets. She holds a master's degree in bioengineering from the University of Washington, a graduate certificate in science writing from UC Santa Cruz and a bachelor's degree in mechanical engineering from the University of Texas at Austin. Tia was part of a team at the Milwaukee Journal Sentinel that published the Empty Cradles series on preterm births, which won multiple awards, including the 2012 Casey Medal for Meritorious Journalism.

  • Wanda
    Thank you, Cepheid. We know you are busting your broncos to get this test into the mainstream as well as hospitals. Kudos.
    Reply